Allovir Stock Performance

ALVR
 Stock
  

USD 7.89  0.04  0.51%   

Allovir holds a performance score of 11 on a scale of zero to a hundred. The firm shows a Beta (market volatility) of 1.4636, which signifies a somewhat significant risk relative to the market. Let's try to break down what Allovir's beta means in this case. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Allovir will likely underperform. Although it is vital to follow Allovir historical returns, it is good to be conservative about what you can do with the information regarding equity current trending patterns. Our philosophy towards foreseeing future performance of any stock is to look not only at its past charts but also at the business as a whole, including all fundamental and technical indicators. To evaluate if Allovir expected return of 1.22 will be sustainable into the future, we have found twenty-eight different technical indicators, which can help you to check if the expected returns are sustainable. Use Allovir treynor ratio, as well as the relationship between the expected short fall and day median price to analyze future returns on Allovir.
  
Allovir Performance
11 of 100
Compared to the overall equity markets, risk-adjusted returns on investments in Allovir are ranked lower than 11 (%) of all global equities and portfolios over the last 90 days. Even with relatively unsteady basic indicators, Allovir reported solid returns over the last few months and may actually be approaching a breakup point. ...more

Allovir Price Channel

Quick Ratio10.81
Fifty Two Week Low3.17
Target High Price34.00
Fifty Two Week High26.41
Target Low Price23.00

Allovir Relative Risk vs. Return Landscape

If you would invest  444.00  in Allovir on July 2, 2022 and sell it today you would earn a total of  341.00  from holding Allovir or generate 76.8% return on investment over 90 days. Allovir is currently generating 1.2191% in daily expected returns and assumes 8.0003% risk (volatility on return distribution) over the 90 days horizon. In different words, 69% of stocks are less volatile than Allovir, and 77% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon.
  Daily Expected Return (%)  
       Risk (%)  
Given the investment horizon of 90 days Allovir is expected to generate 7.05 times more return on investment than the market. However, the company is 7.05 times more volatile than its market benchmark. It trades about 0.15 of its potential returns per unit of risk. The DOW is currently generating roughly -0.08 per unit of risk.

Allovir Market Risk Analysis

Today, many novice investors tend to focus exclusively on investment returns with little concern for Allovir's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Allovir, and traders can use it to determine the average amount a Allovir's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.

Sharpe Ratio = 0.1524

Best
Portfolio
Best
Equity
Good Returns
Average Returns
Small ReturnsALVR
CashSmall
Risk
Average
Risk
High
Risk
Huge
Risk
Negative Returns
Estimated Market Risk
 8.0
  actual daily
 
 69 %
of total potential
 
6969
Expected Return
 1.22
  actual daily
 
 23 %
of total potential
 
2323
Risk-Adjusted Return
 0.15
  actual daily
 
 11 %
of total potential
 
1111
Based on monthly moving average Allovir is performing at about 11% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Allovir by adding it to a well-diversified portfolio.

About Allovir Performance

To evaluate Allovir Stock as a possible investment, you need to clearly understand its upside potential, downside risk, and overall future performance outlook. You may be satisfied when Allovir generates a 15% return over the last few months, but what if the market is generating 25% over the same period? In this case, it makes sense to compare Allovir Stock's performance with different market indexes, such as the Dow or NASDAQ Composite. These indexes can act as benchmarks that will help you to understand Allovir market performance in a much more refined way. The Macroaxis performance score is an integer between 0 and 100 that represents Allovir's market performance from a risk-adjusted return perspective. Generally speaking, the higher the score, the better is overall performance as compared to other investors. The score is normalized against the average investing universe (the best we can interpret from the data available). Within this methodology, scores of individual equity instruments will always be inferior to the scores of portfolios of equities as portfolios typically diversify a lot of unsystematic risks away. The formula to derive the Macroaxis score bases on multiple unequally-weighted factors. For more information, refer to our portfolio performance evaluation section.
Please also refer to our technical analysis and fundamental analysis pages.
Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell therapies to prevent and treat devastating viral-associated diseases. Allovir, Inc. was founded in 2013 and is based in Waltham, Massachusetts. Allovir operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 110 people.

Things to note about Allovir

Checking the ongoing alerts about Allovir for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Allovir help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.

Allovir Alerts

Equity Alerts and Improvement Suggestions

Allovir is way too risky over 90 days horizon
Allovir appears to be risky and price may revert if volatility continues
Net Loss for the year was (184.9 M) with profit before overhead, payroll, taxes, and interest of 165 K.
Allovir currently holds about 201.38 M in cash with (133.87 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.23.
Roughly 35.0% of the company shares are held by company insiders
Please continue to Trending Equities. You can also try Idea Breakdown module to analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes.

Complementary Tools for analysis

When running Allovir price analysis, check to measure Allovir's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Allovir is operating at the current time. Most of Allovir's value examination focuses on studying past and present price action to predict the probability of Allovir's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Allovir's price. Additionally, you may evaluate how the addition of Allovir to your portfolios can decrease your overall portfolio volatility.
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Go
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Go
Transaction History
View history of all your transactions and understand their impact on performance
Go
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated
Go
Probability Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Go
Commodity Channel Index
Use Commodity Channel Index to analyze current equity momentum
Go
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
Go
Shere Portfolio
Track or share privately all of your investments from the convenience of any device
Go
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Go
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Go
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Go
Is Allovir's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Allovir. If investors know Allovir will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Allovir listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Allovir is measured differently than its book value, which is the value of Allovir that is recorded on the company's balance sheet. Investors also form their own opinion of Allovir's value that differs from its market value or its book value, called intrinsic value, which is Allovir's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Allovir's market value can be influenced by many factors that don't directly affect Allovir's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Allovir's value and its price as these two are different measures arrived at by different means. Investors typically determine Allovir value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Allovir's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.